This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Perego, P. Articles by Zunino, F. Search for Related Content PubMed PubMed Citation Articles by Perego, P. Articles by Zunino, F.

Association between Cisplatin Resistance and Mutation of p53 Gene and Reduced Bax Expression in Ovarian Carcinoma Cell Systems¹

Divisions of Experimental Oncology B [P. P., S. R., R. S., C. C., F. Z.] and Experimental Oncology A [D. D., M. G., M. A. P.], Istituto Nazionale Tumori, Via Venezian I, 20133 Milan, Italy, and La Jolla Cancer Research Foundation, La Jolla, California 92037 [T. M., J. C. R]

p53 status may be a determinant of chemosensitivity of tumor cells; however, its involvement in cellular resistance to cisplatin remains uncertain. To investigate the relationships between p53 and the development of resistance to cisplatin, the p53 gene status was studied in ovarian carcinoma cell systems which included two cisplatin-resistant variants (IGROV-1/Pt 0.5 and IGROV-1/Pt 1) selected in vitro after prolonged drug exposure of the cisplatin-sensitive parental IGROV-1 cell line. IGROV-1/Pt 0.5 and IGROV-1/Pt 1 cell lines exhibited a degree of resistance of approximately 6 and 14, respectively, following 96-h exposure to the drug and were cross-resistant to other DNA-damaging agents (ionizing radiation and melphalan). Resistance to cisplatin paralleled a reduced cell susceptibility to cisplatin-induced apoptosis. DNA single-strand conformation polymorphism analysis of exons 5–9 demonstrated the presence of two mutant alleles at exon 8 in the two resistant cell lines, in contrast to the parental IGROV-1 cell line which exhibited the wild-type p53 gene. Direct DNA sequencing revealed that the mutations consist of two nucleotide changes in the DNA-binding domain at codons 270 (T/A) and 282 (C/T). The constitutive levels of p53 protein were lower in IGROV-1 than in IGROV-1/Pt cells. Following exposure to ionizing radiation or cisplatin, accumulation of the p53 protein was markedly enhanced only in the sensitive cells. Concomitantly, the expression of WAF-1 protein was strongly induced in the parental IGROV-1 cells, whereas WAF-1 protein remained undetectable in the IGROV-1/Pt 1 subline after DNA-damaging treatment. Consistent with this finding is the observation that ionizing radiation caused a different pattern of cell cycle perturbation in sensitive and resistant cells. Northern blot analysis demonstrated a marked reduction in bax mRNA levels in IGROV-1/Pt 1 cisplatin-resistant cells. Co-transfection assays with wild-type or mutant p53 expression plasmids and a reporter gene plasmid that utilized the bax gene promoter to drive transcription of chloramphenicol acetyltransferase were consistent with the role of p53 in regulation of bax expression in these cells. Taken together, these observations support a role for mutations of the p53 gene in the development of cisplatin resistance in ovarian cancer as a consequence of loss of the ability of p53 to transactivate bax, an apoptosis-inducing gene.

¹ This work was supported in part by grants from the Consiglio Nazionale delle Ricerche (Finalized Project Applicazioni Cliniche della Ricerca Oncologica), Associazione Italiana per la Ricerca sul Cancro, Ministero della Sanitá, NIH (CA-60181), and American Cancer Society (DHP-32C).

² To whom requests for reprints should be addressed. Phone: 39-2-2390267; Fax: 39-2-2390764.

Received 3/22/95. Accepted 11/20/95.

This article has been cited by other articles:

				M. Muscolini, R. Cianfrocca, A. Sajeva, S. Mozzetti, G. Ferrandina, A. Costanzo, and L. Tuosto Trichostatin A up-regulates p73 and induces Bax-dependent apoptosis in cisplatin-resistant ovarian cancer cells Mol. Cancer Ther., June 1, 2008; 7(6): 1410 - 1419. [Abstract] [Full Text] [PDF]

				V. Benedetti, P. Perego, G. Luca Beretta, E. Corna, S. Tinelli, S. C. Righetti, R. Leone, P. Apostoli, C. Lanzi, and F. Zunino Modulation of survival pathways in ovarian carcinoma cell lines resistant to platinum compounds Mol. Cancer Ther., March 1, 2008; 7(3): 679 - 687. [Abstract] [Full Text] [PDF]

				A. W. Tolcher, D. Hao, J. de Bono, A. Miller, A. Patnaik, L. A. Hammond, L. Smetzer, J. Van Wart Hood, J. Merritt, E. K. Rowinsky, et al. Phase I, Pharmacokinetic, and Pharmacodynamic Study of Intravenously Administered Ad5CMV-p53, an Adenoviral Vector Containing the Wild-Type p53 Gene, in Patients With Advanced Cancer J. Clin. Oncol., May 1, 2006; 24(13): 2052 - 2058. [Abstract] [Full Text] [PDF]

				M. Sakaguchi, T. Nukui, H. Sonegawa, H. Murata, J. Futami, H. Yamada, and N.-h. Huh Targeted disruption of transcriptional regulatory function of p53 by a novel efficient method for introducing a decoy oligonucleotide into nuclei Nucleic Acids Res., May 26, 2005; 33(9): e88 - e88. [Abstract] [Full Text] [PDF]

				M. J. Edelman, J. I. Clark, K. Chansky, K. Albain, N. Bhoopalam, G. R. Weiss, J. K. Giguere, K. Kelly, J. Crowley, and D. R. Gandara Randomized Phase II Trial of Sequential Chemotherapy in Advanced Non-Small Cell Lung Cancer (SWOG 9806): Carboplatin/Gemcitabine followed by Paclitaxel or Cisplatin/Vinorelbine followed by Docetaxel Clin. Cancer Res., August 1, 2004; 10(15): 5022 - 5026. [Abstract] [Full Text] [PDF]

				A. Vekris, D. Meynard, M.-C. Haaz, M. Bayssas, J. Bonnet, and J. Robert Molecular Determinants of the Cytotoxicity of Platinum Compounds: The Contribution of in Silico Research Cancer Res., January 1, 2004; 64(1): 356 - 362. [Abstract] [Full Text] [PDF]

				D. J. Waxman and P. S. Schwartz Harnessing Apoptosis for Improved Anticancer Gene Therapy Cancer Res., December 15, 2003; 63(24): 8563 - 8572. [Abstract] [Full Text] [PDF]

				L. Havrilesky, K. M. Darcy, H. Hamdan, R. L. Priore, J. Leon, J. Bell, and A. Berchuck Prognostic Significance of p53 Mutation and p53 Overexpression in Advanced Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study J. Clin. Oncol., October 15, 2003; 21(20): 3814 - 3825. [Abstract] [Full Text] [PDF]

				T. Petit, D. J. Bearss, D. A. Troyer, R. M. Munoz, and J. J. Windle p53-independent Response to Cisplatin and Oxaliplatin in MMTV-ras Mouse Salivary Tumors Mol. Cancer Ther., February 1, 2003; 2(2): 165 - 171. [Abstract] [Full Text] [PDF]

				G. Pratesi, M. De Cesare, N. Carenini, P. Perego, S. C. Righetti, C. Cucco, L. Merlini, C. Pisano, S. Penco, P. Carminati, et al. Pattern of Antitumor Activity of a Novel Camptothecin, ST1481, in a Large Panel of Human Tumor Xenografts Clin. Cancer Res., December 1, 2002; 8(12): 3904 - 3909. [Abstract] [Full Text] [PDF]

				F. Riva, V. Zuco, A. A. Vink, R. Supino, and E. Prosperi UV-induced DNA incision and proliferating cell nuclear antigen recruitment to repair sites occur independently of p53-replication protein A interaction in p53 wild type and mutant ovarian carcinoma cells Carcinogenesis, December 1, 2001; 22(12): 1971 - 1978. [Abstract] [Full Text] [PDF]

				R. D. Abeysinghe, B. T. Greene, R. Haynes, M. C. Willingham, J. Turner, R. P. Planalp, M.W. Brechbiel, F. M. Torti, and S. V. Torti p53-independent apoptosis mediated by tachpyridine, an anti-cancer iron chelator Carcinogenesis, October 1, 2001; 22(10): 1607 - 1614. [Abstract] [Full Text] [PDF]

				P. Perego, M. De Cesare, P. De Isabella, N. Carenini, G. Beggiolin, G. Pezzoni, M. Palumbo, L. Tartaglia, G. Pratesi, C. Pisano, et al. A Novel 7-modified Camptothecin Analog Overcomes Breast Cancer Resistance Protein-associated Resistance in a Mitoxantrone-selected Colon Carcinoma Cell Line Cancer Res., August 1, 2001; 61(16): 6034 - 6037. [Abstract] [Full Text] [PDF]

				N. Keshelava, J. J. Zuo, P. Chen, S. N. Waidyaratne, M. C. Luna, C. J. Gomer, T. J. Triche, and C. P. Reynolds Loss of p53 Function Confers High-Level Multidrug Resistance in Neuroblastoma Cell Lines Cancer Res., August 1, 2001; 61(16): 6185 - 6193. [Abstract] [Full Text] [PDF]

				M. A. Shah and G. K. Schwartz Cell Cycle-mediated Drug Resistance: An Emerging Concept in Cancer Therapy Clin. Cancer Res., August 1, 2001; 7(8): 2168 - 2181. [Abstract] [Full Text] [PDF]

				J. Li, Q. Feng, J.-M. Kim, D. Schneiderman, P. Liston, M. Li, B. Vanderhyden, W. Faught, M. F. K. Fung, M. Senterman, et al. Human Ovarian Cancer and Cisplatin Resistance: Possible Role of Inhibitor of Apoptosis Proteins Endocrinology, January 1, 2001; 142(1): 370 - 380. [Abstract] [Full Text] [PDF]

				V. Masciullo, G. Ferrandina, B. Pucci, F. Fanfani, S. Lovergine, J. Palazzo, G. Zannoni, S. Mancuso, G. Scambia, and A. Giordano p27Kip1 Expression Is Associated with Clinical Outcome in Advanced Epithelial Ovarian Cancer: Multivariate Analysis Clin. Cancer Res., December 1, 2000; 6(12): 4816 - 4822. [Abstract] [Full Text]

				C. Heise, M. Lemmon, and D. Kirn Efficacy with a Replication-selective Adenovirus Plus Cisplatin-based Chemotherapy: Dependence on Sequencing but not p53 Functional Status or Route of Administration Clin. Cancer Res., December 1, 2000; 6(12): 4908 - 4914. [Abstract] [Full Text]

				H. Sasaki, Y. Sheng, F. Kotsuji, and B. K. Tsang Down-Regulation of X-linked Inhibitor of Apoptosis Protein Induces Apoptosis in Chemoresistant Human Ovarian Cancer Cells Cancer Res., October 1, 2000; 60(20): 5659 - 5666. [Abstract] [Full Text]

				M. A. Levesque, D. Katsaros, M. Massobrio, F. Genta, H. Yu, G. Richiardi, S. Fracchioli, A. Durando, R. Arisio, and E. P. Diamandis Evidence for a Dose-Response Effect between p53 (but not p21WAF1/Cip1) Protein Concentrations, Survival, and Responsiveness in Patients with Epithelial Ovarian Cancer Treated with Platinum-based Chemotherapy Clin. Cancer Res., August 1, 2000; 6(8): 3260 - 3270. [Abstract] [Full Text]

				A. Cabelguenne, H. Blons, I. de Waziers, F. Carnot, A.-M. Houllier, T. Soussi, D. Brasnu, P. Beaune, O. Laccourreye, and P. Laurent-Puig p53 Alterations Predict Tumor Response to Neoadjuvant Chemotherapy in Head and Neck Squamous Cell Carcinoma: A Prospective Series J. Clin. Oncol., April 7, 2000; 18(7): 1465 - 1473. [Abstract] [Full Text] [PDF]

				E Maellaro, S Dominici, B Del Bello, M. Valentini, L Pieri, P Perego, R Supino, F Zunino, E Lorenzini, A Paolicchi, et al. Membrane gamma-glutamyl transpeptidase activity of melanoma cells: effects on cellular H(2)O(2) production, cell surface protein thiol oxidation and NF-kappa B activation status J. Cell Sci., January 8, 2000; 113(15): 2671 - 2678. [Abstract] [PDF]

				L. Lassaletta, J. A. Brandariz, A. Benito, J. de la Cruz, C. Gomez, C. Ballestin, R. Hitt, R. Colomer, and J. J. Alvarez-Vicent p53 Expression in Locally Advanced Pharyngeal Squamous Cell Carcinoma Arch Otolaryngol Head Neck Surg, December 1, 1999; 125(12): 1356 - 1359. [Abstract] [Full Text] [PDF]

				H. Shiga, E. I. Heath, A. A. Rasmussen, B. Trock, P. G. Johnston, A. A. Forastiere, M. Langmacher, A. Baylor, M. Lee, and K. J. Cullen Prognostic Value of p53, Glutathione S-Transferase {{pi}}, and Thymidylate Synthase for Neoadjuvant Cisplatin-based Chemotherapy in Head and Neck Cancer Clin. Cancer Res., December 1, 1999; 5(12): 4097 - 4104. [Abstract] [Full Text] [PDF]

				S. C. Righetti, P. Perego, E. Corna, M. A. Pierotti, and F. Zunino Emergence of p53 Mutant Cisplatin-resistant Ovarian Carcinoma Cells following Drug Exposure:Spontaneously Mutant Selection Cell Growth Differ., July 1, 1999; 10(7): 473 - 478. [Abstract] [Full Text]

				B. Leyland-Jones, L. R. Kelland, K. R. Harrap, and L. R. Hiorns Genomic Imbalances Associated with Acquired Resistance to Platinum Analogues Am. J. Pathol., July 1, 1999; 155(1): 77 - 84. [Abstract] [Full Text] [PDF]

				C. G. Maki Oligomerization Is Required for p53 to be Efficiently Ubiquitinated by MDM2 J. Biol. Chem., June 4, 1999; 274(23): 16531 - 16535. [Abstract] [Full Text] [PDF]

				P. L. Judson, J. M. Watson, P. A. Gehrig, W. C. Fowler Jr., and J. S. Haskill Cisplatin Inhibits Paclitaxel-induced Apoptosis in Cisplatin-resistant Ovarian Cancer Cell Lines: Possible Explanation for Failure ofCombination Therapy Cancer Res., May 1, 1999; 59(10): 2425 - 2432. [Abstract] [Full Text] [PDF]

				P. Perego, C. Caserini, L. Gatti, N. Carenini, S. Romanelli, R. Supino, D. Colangelo, I. Viano, R. Leone, S. Spinelli, et al. A Novel Trinuclear Platinum Complex Overcomes Cisplatin Resistance in an Osteosarcoma Cell System Mol. Pharmacol., March 1, 1999; 55(3): 528 - 534. [Abstract] [Full Text]

				L. Cremonesi, P. Carrera, A. Fumagalli, S. Lucchiari, E. Cardillo, M. Ferrari, S. C. Righetti, F. Zunino, P. G. Righetti, and C. Gelfi Validation of Double Gradient Denaturing Gradient Gel Electrophoresis through Multigenic Retrospective Analysis Clin. Chem., January 1, 1999; 45(1): 35 - 40. [Abstract] [Full Text] [PDF]

				E. W. Newcomb, M. Sosnow, R. I. Demopoulos, A. Zeleniuch-Jacquotte, J. Sorich, and J. L. Speyer Expression of the Cell Cycle Inhibitor p27KIP1 Is a New Prognostic Marker Associated with Survival in Epithelial Ovarian Tumors Am. J. Pathol., January 1, 1999; 154(1): 119 - 125. [Abstract] [Full Text] [PDF]

				P. Perego, F. Zunino, N. Carenini, F. Giuliani, S. Spinelli, and S. B. Howell Sensitivity to Cisplatin and Platinum-Containing Compounds of Schizosaccharomyces pombe Rad Mutants Mol. Pharmacol., July 1, 1998; 54(1): 213 - 219. [Abstract] [Full Text]

				D. B. Zamble, T. Jacks, and S. J. Lippard p53-dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells PNAS, May 26, 1998; 95(11): 6163 - 6168. [Abstract] [Full Text] [PDF]

				N. A. Jones, J. Turner, A. J. McIlwrath, R. Brown, and C. Dive Cisplatin- and Paclitaxel-Induced Apoptosis of Ovarian Carcinoma Cells and the Relationship between Bax and Bak Up-Regulation and the Functional Status of p53 Mol. Pharmacol., May 1, 1998; 53(5): 819 - 826. [Abstract] [Full Text]

				T. Yamada, R. Endo, M. Gotoh, and S. Hirohashi Identification of semaphorin E as a non-MDR drug resistance gene of human cancers PNAS, December 23, 1997; 94(26): 14713 - 14718. [Abstract] [Full Text] [PDF]

				J. V. Thottassery, G. P. Zambetti, K. Arimori, E. G. Schuetz, and J. D. Schuetz p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents PNAS, September 30, 1997; 94(20): 11037 - 11042. [Abstract] [Full Text] [PDF]

				B. C. Ding, J. R. Whetstine, T. L. Witt, J. D. Schuetz, and L. H. Matherly Repression of Human Reduced Folate Carrier Gene Expression by Wild Type p53 J. Biol. Chem., March 16, 2001; 276(12): 8713 - 8719. [Abstract] [Full Text] [PDF]

				P. Casalini, L. Botta, and S. Menard Role of p53 in HER2-induced Proliferation or Apoptosis J. Biol. Chem., April 6, 2001; 276(15): 12449 - 12453. [Abstract] [Full Text] [PDF]